The Catalyser programme helps companies innovating in human health refine their commercialisation strategy through a journey involving the analysis of 9 meso-economic vectors from the Triple Chasm framework.

The 2025 cohort comprises of  8 companies at pre-clinical stage.  From the programme, these companies will gain:

  • a refined commercialisation strategy
  • a clear execution plan
  • access to experts, potential partners and investors
  • CRO services: Pharmidex will provide a tailored package to a select number of companies

The 6 highly-interactive sessions cover the strategy vectors:

  • Market Space Definition
  • Proposition Framing + Customer Definition
  • Tech Management + IP Management
  • Product Synthesis + Human Capital
  • Funding Strategy + Strategic Positioning – Presentation by Dr Anne Horgan, Partner at Cambridge Innovation Capital 
  • Final Presentations and Feedback